Discovery and development of respirable antisense therapeutics for asthma

Antisense and Nucleic Acid Drug Development

Volumn 12, Issue 3, 2002, Pages 177-181

  Sandrasagra, Anthony ^a   Leonard, Sherry A ^a   Tang, Lei ^a   Teng, Kelly ^a   Li, Yukui ^a   Ball, Howard A ^a   Mannion, James C ^a   Nyce, Jonathan W ^a  

^a Epigenesis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; EPI 2010; G PROTEIN COUPLED RECEPTOR; PHOSPHOROTHIOIC ACID DERIVATIVE; EPI2010; PHOSPHATE;

AEROSOL; ASTHMA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; HUMAN; MEDICAL GENETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; CARDIOVASCULAR SYSTEM; DRUG DESIGN; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALIA;

ADMINISTRATION, INHALATION; ASTHMA; CARDIOVASCULAR SYSTEM; DRUG DESIGN; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATES; TISSUE DISTRIBUTION;

EID: 0035992686     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729002760220770     Document Type: Review

References (31)

1. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides
2. Antisense therapeutics
3. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma
4. Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: Evidence for an inducible adenosine A1 receptor
5. Asthma-United States, 1982-1992
6. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine
7. A hitchhiker's guide to antisense and nonantisense biochemical pathways
8. Control of scarring in adult wounds using antisense transforming growth factor-beta 1 oligodeoxynucleotides
9. A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells
10. An overview of progress in antisense therapeutics
11. Fomivirsen: A phosphorothioate oligonucleotide for the treatment of CMV retinitis
12. Adenosine in bronchoalveolar lavage fluid in asthma
13. Characterization of adenosine receptor involved in adenosine-induced bronchoconstriction in allergic rabbits
14. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma
15. Treatment of allergic airway inflammation and hyperresponsiveness by antisense induced local blockade of GATA-3 expression
16. A2 and P2 purine receptor interactions and surfactant secretion in primary cultures of type II cells
17. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomologus monkeys following intravenous infusion
18. An antisense oligonucleotide primer
19. From bugs to drugs: Therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA
20. In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide
21. A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense nucleotides
22. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP-64128A): Comparison with other delivery routes
23. 1 adenosine receptor expression by activating nuclear factor kappa B
24. Insight into adenosine receptor function using antisense and gene-knockout approaches
25. DNA antisense therapy for asthma in an animal model
26. Characterization of the adenosine receptors in the airways
27. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
28. Changing patterns in asthma morbidity and mortality
29. Related articles pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice
30. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration